Syngene Inks Pact with GSK for Drug Discovery Services
Bengaluru based contract research services firm, Syngene International, has entered into an R&D agreement with healthcare major GSK. The multi-year agreement will focus on accelerating the discovery of new drug candidates using Syngene’s discovery services platform, Sygene said in a statement.
As per this agreement, Syngene will set up a discovery research laboratory to support projects across several therapeutic areas. Also, a team of Syngene scientists will work closely with GSK’s global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world’s most pressing healthcare needs. Mr. Jonathan Hunt, Chief Executive Officer, Syngene International, said, “The collaboration in many ways underlines Syngene’s position as an innovative, capable and cost-effective provider of discovery research services to the global pharma industry.”
Looking for chemical products? Let suppliers reach out to you!
2026-07-03
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Syngene Acquires Its First US Manufacturing Facility
-
The Controversial Billion-Dollar Tuition: The Story Behind Hengrui's BD Dispute
-
Again, GSK failed to make the case that Mersana's excited HER2 ADC led to death and clinical suspension
-
3 billion, nearly 10 years, why GlaxoSmithKline again?
-
FDA Approves First New Measles, Mumps and Rubella Vaccine in 50 Years
-
Novo Nordisk Submits Higher Dose of Wegovy One in Three Achieves Over 25 Percent Weight Loss
-
Lilly Bets Bigger on China
-
Rising API Costs Threaten Drug Prices
-
Eisai Pharma Unveils Bold Plan: $100 Million Global Center Set to Transform Visakhapatnam Now
-
Over 70% of Patients Find Relief in Bayer’s New Breakthrough Drug for Breast Cancer Menopause Symptoms
Recommend Reading
-
BioNTech’s Founders Turn the Page
-
India’s API Trade Balance Turns Positive
-
Novo Nordisk Faces a Compliance Test
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Polyvantis Opens Shanghai Technical Center
-
Following Cost Fluctuations, Polyester Staple Fiber Prices Stop Falling and Rebound
-
Acesulfame Potassium: Safety, Side Effects, and Food Uses
-
Supply and Demand Weakness, Flexible Fluctuations in the Melamine Market
-
Paint Giant PPG Announces Global Price Hike